These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24821101)

  • 1. The pathophysiology of thyroid eye disease.
    Shan SJ; Douglas RS
    J Neuroophthalmol; 2014 Jun; 34(2):177-85. PubMed ID: 24821101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TSHR-IGF-IR complex drives orbital fibroblast misbehavior in thyroid eye disease.
    Smith TJ
    Curr Opin Endocrinol Diabetes Obes; 2024 Oct; 31(5):177-183. PubMed ID: 39082947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoints: new insights into the pathogenesis of thyroid eye disease.
    Shu X; Shao Y; Chen Y; Zeng C; Huang X; Wei R
    Front Immunol; 2024; 15():1392956. PubMed ID: 38817600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid-associated eye disease.
    Heufelder AE; Joba W
    Strabismus; 2000 Jun; 8(2):101-11. PubMed ID: 10980691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.
    Girnita L; Smith TJ; Janssen JAMJL
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S1-S12. PubMed ID: 35167695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor.
    Smith TJ; Hoa N
    J Clin Endocrinol Metab; 2004 Oct; 89(10):5076-80. PubMed ID: 15472208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orbital Signaling in Graves' Orbitopathy.
    Draman MS; Zhang L; Dayan C; Ludgate M
    Front Endocrinol (Lausanne); 2021; 12():739994. PubMed ID: 34899596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid eye disease: From pathogenesis to targeted therapies.
    Yoon JS; Kikkawa DO
    Taiwan J Ophthalmol; 2022; 12(1):3-11. PubMed ID: 35399971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological Aspects of Graves' Ophthalmopathy.
    Łacheta D; Miśkiewicz P; Głuszko A; Nowicka G; Struga M; Kantor I; Poślednik KB; Mirza S; Szczepański MJ
    Biomed Res Int; 2019; 2019():7453260. PubMed ID: 31781640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathophysiology of thyroid eye disease: implications for immunotherapy.
    Douglas RS; Gupta S
    Curr Opin Ophthalmol; 2011 Sep; 22(5):385-90. PubMed ID: 21730841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunopathogenesis of thyroid eye disease: emerging paradigms.
    Naik VM; Naik MN; Goldberg RA; Smith TJ; Douglas RS
    Surv Ophthalmol; 2010; 55(3):215-26. PubMed ID: 20385333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune thyroid diseases: genetic susceptibility of thyroid-specific genes and thyroid autoantigens contributions.
    Hadj-Kacem H; Rebuffat S; Mnif-Féki M; Belguith-Maalej S; Ayadi H; Péraldi-Roux S
    Int J Immunogenet; 2009 Apr; 36(2):85-96. PubMed ID: 19284442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pentraxin-3 Is a TSH-Inducible Protein in Human Fibrocytes and Orbital Fibroblasts.
    Wang H; Atkins SJ; Fernando R; Wei RL; Smith TJ
    Endocrinology; 2015 Nov; 156(11):4336-44. PubMed ID: 26287404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multicenter, Single-Blind, Case-Control, Immunohistochemical Study of Orbital Tissue in Thyroid Eye Disease.
    Hai YP; Saeed MEM; Ponto KA; Elflein HM; Lee ACH; Fang S; Zhou H; Frommer L; Längericht J; Efferth T; Kahaly GJ
    Thyroid; 2022 Dec; 32(12):1547-1558. PubMed ID: 36128805
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of an animal model of autoimmune thyroid eye disease.
    Many MC; Costagliola S; Detrait M; Denef F; Vassart G; Ludgate MC
    J Immunol; 1999 Apr; 162(8):4966-74. PubMed ID: 10202044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological Processes in the Orbit and Indications for Current and Potential Drug Targets.
    Cieplińska K; Niedziela E; Kowalska A
    J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms.
    Khong JJ; McNab AA; Ebeling PR; Craig JE; Selva D
    Br J Ophthalmol; 2016 Jan; 100(1):142-50. PubMed ID: 26567024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid eye disease: therapy in the active phase.
    Bhatti MT; Dutton JJ
    J Neuroophthalmol; 2014 Jun; 34(2):186-97. PubMed ID: 24821102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current understanding of pathogenesis of Graves ophthalmopathy].
    Ando T; Eguchi K
    Nihon Rinsho; 2006 Dec; 64(12):2275-8. PubMed ID: 17154091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of the Immune Response in the Pathogenesis of Thyroid Eye Disease: A Reassessment.
    Rosenbaum JT; Choi D; Wong A; Wilson DJ; Grossniklaus HE; Harrington CA; Dailey RA; Ng JD; Steele EA; Czyz CN; Foster JA; Tse D; Alabiad C; Dubovy S; Parekh PK; Harris GJ; Kazim M; Patel PJ; White VA; Dolman PJ; Edward DP; Alkatan HM; Al Hussain H; Selva D; Yeatts RP; Korn BS; Kikkawa DO; Stauffer P; Planck SR
    PLoS One; 2015; 10(9):e0137654. PubMed ID: 26371757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.